Osborne Clarke has advised naturalX Health Ventures, the venture capital arm of Schwabe Group, on its investment in a Series A funding round in nutritional supplement start-up mybacs.
mybacs aims to revolutionise the health market around the human microbiome. To achieve this, the company, which is based in Munich and Zug, Switzerland, focuses on synbiotic food supplements that are tailored to the individual needs and areas of use of its consumers through their formulation of specifically selected bacterial cultures, prebiotics, minerals and vitamins.
Founded in 2018 by Sebastian Wahl and Carl-Philipp von Polheim, the company has now successfully closed its Series A financing round. In total, the investors provided capital of EUR 5.6 million. In addition to naturalX Health Ventures, other investors included Wenvest Capital and SevenVentures, as well as legacy investors Global Founders Capital (GFC) and Joyance Partners.
The Osborne Clarke team advising naturalX Health Ventures, led by Till-Manuel Saur, consisted of Fenja Striesow, Robert Marx, Benedikt Hülsmann and Philipp Niedermeyer, (all Corporate / VC), Florian Merkle, Pascal Franz (both Tax), Dr Jens Schefzig, Timo Bosman (both Data Protection), Dr Lina Böcker, Leonie Schneider, Maximilian Bodamer, Tim Schmetzer, Juliana Trouet (all IT), Dr Jonas Völkel, Lotte Mues (both IP), Johanna Reiland, Nils-Frederik Wiehmann, Johanna Sophie Sittner (all Labour Law), Sarah Grigo and Dr Philipp Stein (both Commercial).